# Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.

> **NCT00238745** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 375 (—)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Bazedoxifene
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00238745
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 375 (—)
- **Last updated:** 2007-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00238745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00238745, "Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00238745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*